The earnings call highlighted significant advancements in clinical trials and AI platform development, demonstrating both financial discipline and strategic expansion. However, challenges remain in securing additional funding and successfully commercializing AI data modules.

Company Guidance

In the first quarter of 2025, Lantern Pharma made significant progress in its clinical pipeline and AI platform advancements, setting the stage for multiple catalysts in the coming quarters. The company advanced its Phase 1a trial for LP-184, with enrollment nearing completion at 62 to 65 patients, and began observing early indications of clinical activity. Lantern's proprietary radar AI platform expanded to over 200 billion oncology-focused data points, and the company announced plans to commercialize its AI modules, starting with a blood-brain barrier prediction tool. Financially, Lantern reduced its net loss to approximately $4.5 million, down from $5.4 million the previous year, while maintaining a cash position of $19.7 million. The company also highlighted strategic initiatives for maximizing shareholder value, including potential partnerships and commercialization of AI capabilities.

Clinical Pipeline Advancements

The Phase 1a trial for LP-184 is progressing well, with enrollment expected to be complete by June 2025. Dual fast track designations for LP-184 in glioblastoma and triple-negative breast cancer have been granted, opening paths toward regulatory approvals.

AI Platform Expansion

The radar AI platform has expanded to over 200 billion oncology-focused data points. Plans are in place to open the platform to the scientific community, potentially creating new revenue streams.

Financial Discipline and Efficiency

Quarterly net loss decreased to $4.5 million from $5.4 million the previous year, demonstrating operational efficiency. Cash and marketable securities stand at $19.7 million, providing runway until at least mid-May 2026.

HARMONIC Phase 2 Trial Progress

Strong progress in the HARMONIC trial for LP-300, with positive preliminary data showing an 86% clinical benefit rate. Expansion in Asian markets is underway.

Lantern Pharma (LTRN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LTRN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.47 / -	-0.42	―	―	―
Aug 13, 2025	2025 (Q2)	-0.44 / -0.40	-0.46	13.04% (+0.06)	―	―
May 15, 2025	2025 (Q1)	-0.49 / -0.42	-0.51	17.65% (+0.09)
Mar 27, 2025	2024 (Q4)	-0.51 / -0.54	-0.39	-38.46% (-0.15)
Nov 07, 2024	2024 (Q3)	-0.56 / -0.42	-0.29	-44.83% (-0.13)
Aug 08, 2024	2024 (Q2)	-0.55 / -0.46	-0.44	-4.55% (-0.02)
May 09, 2024	2024 (Q1)	-0.43 / -0.51	-0.36	-41.67% (-0.15)
Mar 18, 2024	2023 (Q4)	-0.40 / -0.39	-0.31	-25.81% (-0.08)
Nov 08, 2023	2023 (Q3)	-0.48 / -0.29	-0.21	-38.10% (-0.08)
Aug 09, 2023	2023 (Q2)	-0.43 / -0.44	-0.41	-7.32% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LTRN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$4.76	$4.57	-3.99%
May 15, 2025	$4.06	$3.86	-4.93%
Mar 27, 2025	$3.72	$3.55	-4.57%
Nov 07, 2024	$3.42	$3.84	+12.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lantern Pharma, Inc. (LTRN) report earnings?

Lantern Pharma, Inc. (LTRN) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Lantern Pharma, Inc. (LTRN) earnings time?

Lantern Pharma, Inc. (LTRN) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LTRN EPS forecast?

LTRN EPS forecast for the fiscal quarter 2025 (Q3) is -0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing